The much-anticipated data from Amgen Inc.'s pivotal fracture study of denosumab in postmenopausal women demonstrated a significant reduction in vertebral fracture rate and relatively clean safety profile, ending a month and a half of speculation among investors since top-line data were released in late July. (BioWorld Today) Read More
